Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» psoriasis
psoriasis
The other shoe drops for Immunic
EP Vantage
Fri, 10/21/22 - 10:19 am
Immunic
IMU-935
psoriasis
A biologic’s efficacy in a pill: Dice posts first human data for oral psoriasis med
MedCity News
Tue, 10/11/22 - 03:59 pm
DiCE Therapeutics
biologics
psoriasis
DC-806
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
BioPharma Dive
Mon, 09/12/22 - 11:39 pm
Nimbus Therapeutics
psoriasis
Bristol Myers Squibb
Sotyktu
Bristol Myers gets FDA approval for new type of psoriasis drug
BioPharma Dive
Sun, 09/11/22 - 11:09 pm
Bristol Myers Squibb
Sotyktu
FDA
psoriasis
Ventyx touts early data for potential rival to Bristol Myers psoriasis drug
BioPharma Dive
Tue, 08/16/22 - 12:22 pm
Ventyx Biosciences
clinical trials
Bristol Myers Squibb
psoriasis
VTX958
deucravacitinib
Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial
Fierce Biotech
Wed, 08/10/22 - 10:49 am
Innovent
AbbVie
JNJ
monoclonal antibodies
psoriasis
clinical trials
Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Clinical Trials Arena
Tue, 08/9/22 - 06:32 am
clinical trials
psoriasis
psoriatic arthritis
Lipidor
AKP-02
Amgen
ABP-654
Hengyi
HPP-737
Galapagos
Jyseleca
FDA Action Alert: Incyte, Arcutis Await Decisions in Vitiligo, Psoriasis
BioSpace
Mon, 07/18/22 - 10:22 am
FDA
Incyte
Arcutis Biotherapeutics
Opzelura
vitiligo
roflumilast
psoriasis
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test
Fierce Biotech
Wed, 06/1/22 - 09:48 am
Bristol Myers Squibb
lupus
psoriasis
deucravacitinib
FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years
MedCity News
Tue, 05/24/22 - 04:40 pm
Roivant
Vtama
FDA
psoriasis
plaque psoriasis
J&J's crown jewel Stelara faces another potential rival as biosim player Alvotech touts trial win
Fierce Pharma
Tue, 05/24/22 - 04:31 pm
Alvotech
Teva Pharmaceutical
JNJ
Stelara
AVT04
biosimilars
psoriasis
UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug
MedCity News
Sun, 05/15/22 - 11:12 pm
UCB Pharma
bimekizumab
psoriasis
FDA
JNJ
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
Fierce Biotech
Thu, 05/12/22 - 10:48 am
Bristol Myers Squibb
deucravacitinib
clinical trials
psoriasis
Amgen
Otezla
Psoriasis and psoriatic arthritis drugs crisscross categories, but derm and rheum docs split on preferences
Endpoints
Mon, 05/9/22 - 11:35 pm
psoriasis
psoriatic arthritis
dermatologists
rheumatologists
FDA knocks Bausch for misleading promotion of psoriasis drug on Lifetime show
RAPS.org
Tue, 04/12/22 - 08:42 pm
Bausch Health
FDA
OPDP
psoriasis
Doubrii
Amgen builds Otezla’s psoriasis label as rival BMS looms large
Pharmaforum
Wed, 12/22/21 - 11:19 am
Amgen
Otezla
psoriasis
Bristol Myers Squibb
deucravacitinib
Amgen's Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rival
Fierce Pharma
Thu, 12/2/21 - 12:25 pm
Amgen
Otezla
psoriasis
Bristol Myers Squibb
Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster
Fierce Biotech
Thu, 10/7/21 - 11:24 am
Bristol Myers Squibb
deucravacitinib
Amgen
Otzela
psoriasis
ulcerative colitis
Go or no go? UCB bids to make a mark in psoriasis
EP Vantage
Mon, 10/4/21 - 10:35 am
UCB Pharma
Bimzelx
psoriasis
Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028
Fierce Pharma
Tue, 09/21/21 - 10:54 am
Amgen
Otezla
psoriasis
generics
Sandoz
market exclusivity
patents
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »